BackAscelia Pharma AB (publ) Overview

Ascelia Pharma AB (publ) EBIT

Ascelia Pharma AB (publ)'s EBIT is $-56M, below the Healthcare sector average of $1.9T.

Get informed when a big investor buys or sells

+ Follow

Quarterly EBIT

-$10.50M
↑ 29.19% YoY

As of Sep 30, 2026

Annual EBIT (TTM)

-$55.60M
↑ 27.91% YoY

Trailing 12 months ending Sep 30, 2026

Average EBIT (Comparison Companies)

EBIT History

EBIT Comparison

Annual EBIT Growth Rate (%)

Annual EBIT Growth (Absolute)

Ascelia Pharma AB (publ) (ACE.ST) FAQ

The latest EBIT for ACE.ST is $-56M as of September 2026. That compares with $-77M in the prior-year period — up 27.9% year over year. That is below the Healthcare sector average of $1.9T. Investors often review this figure alongside Ascelia Pharma AB (publ)'s historical trend and sector peers before judging valuation or financial health.

Over the past year, ACE.ST's EBIT moved from $-77M to $-56M — a 27.9% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Ascelia Pharma AB (publ)'s operating scale or balance-sheet position.

Against Healthcare companies, ACE.ST currently prints $-56M for EBIT, while the sector average sits near $1.9T. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at Ascelia Pharma AB (publ)'s growth, margins, and balance sheet.

A EBIT figure of $-56M for ACE.ST is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $1.9T. Explore the charts below for those layers of context.

After noting ACE.ST's EBIT ($-56M), review year-over-year change from $-77M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.